Clinical trial
The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
NCT00255476 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00255476 |
|---|---|
| Title | The IRESSA Novel Head and Neck Chemotherapy Evaluation Study |
| Official title | A Randomised Phase II Study to Investigate the Feasibility and Benefits of Combining ZD1839 and Cisplatin/5FU, as Induction Therapy, in Patients With Locally and Advanced Squamous Cell Carcinoma of the Head and Neck |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Squamous Cell Cancer, Cancer of Head and Neck |
| Intervention type | Drug |
| Interventions | gefitinib, cisplatin, 5-flourouracil |
| Enrollment | 64 |
| Start date | Feb 1, 2004 |
| Completion | Jul 1, 2007 |
| First posted | Nov 21, 2005 |
| Last update posted | Apr 23, 2009 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: